secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0001104659-24-129181
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics awarded $9.5M CPRIT grant for MT-601 in pancreatic cancer study
--------------------------------------------------------------------------------

- Received $9.5M non-dilutive grant from CPRIT to support Phase 1 PANACEA study of MT-601 in metastatic pancreatic cancer.
- Also received $2M NIH SBIR grant; total non-dilutive funding exceeds $30M from FDA, NIH, and CPRIT.
- Clinical program initiation for MT-601 in pancreatic cancer expected in 2025.
- Preliminary data from prior multiTAA-specific T cell study showed 1 CR, 3 PRs, 6 SD in 13 pancreatic cancer patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924129181/0001104659-24-129181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924129181/tm2431191d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-129181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer